Bringing care closer to home with Breathe RM
Breathe RM is a remote monitoring solution created by Magic Bullet, a not-for-profit social enterprise. Specialising in digital care technology for cystic fibrosis patients since 2017, we are committed to working with NHS teams to meet the care demands of modern cystic fibrosis and respiratory clinic services.
Breathe RM is evolving to improve hospital and ICB outcomes.
Our platform enables:
Decrease frequency of routine in-hospital visits, while mitigating gaps in care visibility which may arise during virtual care.
With longitudinal data, spot trends and intervene early to reduce patient exacerbations and hospital admissions, in line with admission avoidance targets.
Optimise clinic resources, enabling care teams to prioritise time in clinic with patients who are most in need.
Meeting the care demands of modern CF and respiratory clinic services.
We will work with you to build the remote monitoring program that fits your clinic needs, providing the bespoke service you require.
Breathe RM complies with UKCA and CE Class I software as a medical device, DCB0129, DTAC, Cyber Essentials, and ISO9001 regulations. All data is securely encrypted and stored in compliance with GDPR standards.
Service set up and onboarding with Breathe RM is secure and simple. Everything is handled remotely via our web portal, and we’ll provide all the training and support you need.
The Breathe RM evidence base:
Remote monitoring technologies are now used in CF clinics in the UK, Europe and the US. Virtual monitoring in cystic fibrosis has been shown to be acceptable, feasible, and usable with the potential to positively impact health outcomes. (1)
Remote monitoring unlocks a higher standard of care for patients who cannot frequently travel to clinics, are most at risk of exacerbations and those who prefer a virtual care model. Applications to support physiotherapist exercise prescriptions, sputum surveillance and sweat chloride measurements in patients who are prescribed highly effective modulator therapy (HEMT) are also being investigated (2).
Our inaugural multi-site trial, Project Breathe, assessed the feasibility of virtual data collection and remote monitoring in adults with cystic fibrosis. The trial ended in January 2024. Analysis of trial data is ongoing.
Two follow up trials, BRONCH-EX and ACE-CF (3), have received funding from National Institute of Health & Social Care (NIHR) and LifeArc. These trials are now underway and will investigate the use of machine learning to predict pulmonary exacerbations.
In early 2024 Breathe RM Director, Kirsty Hill, was selected as a Patient Innovator on the prestigious NHS Clinician Entrepreneur Program (CEP).
We are pleased to be collaborating with Health Innovation Wessex to maximise the potential and utility of remote monitoring in clinical practice.
-
Vagg T, Deasy KF, Chapman WW, Ranganathan SC, Plant BJ, Shanthikumar S. Virtual monitoring in CF - the importance of continuous monitoring in a multi-organ chronic condition. Front Digit Health. 2023 May 4;5:1196442. doi: 10.3389/fdgth.2023.1196442. PMID: 37214343; PMCID: PMC10192704.
-
Vagg T, Deasy KF, Chapman WW, Ranganathan SC, Plant BJ, Shanthikumar S. Virtual monitoring in CF - the importance of continuous monitoring in a multi-organ chronic condition. Front Digit Health. 2023 May 4;5:1196442. doi: 10.3389/fdgth.2023.1196442. PMID: 37214343; PMCID: PMC10192704.
Breathe RM Articles
Considering Breathe RM for your clinic?
From clinical trials to clinics and community care. Connect with us, or book a demo at a time that suits you.
